Abstract
A 5-year phase I/II with an expanded phase II study of 101 patients has been recently reported. A subgroup of patients with advanced leiomyosarcoma (LMS) participated in the study. Hypothesis: Sarcoma tumors are more immunogenic at the onset of disease. Immune checkpoint inhibitors that promote sustained T cell activation would be most effective when given as first line therapy, together with a tumoricidal agent such as Trabectedin that depletes growth promoting macrophages in the tumor microenvironment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
